Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros










Intervalo de ano de publicação
2.
Transfus Apher Sci ; 60(2): 103046, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33455879

RESUMO

The recurrence of primary focal segmental glomerulosclerosis (FSGS) after kidney transplantation (KT) appears in 30 % of the recipients. Sometimes it can cause the loss of the allograft. Although many treatments for this condition have been reported, 20 %-40 % of the affected patients are refractory or presents frequents relapses. In this paper we describe the evolution of three recipients treated with long-term plasmapheresis therapy after a recurrence of FSGS with a bad or incomplete response to other treatments. Although our findings require confirmation, long-term plasmapheresis could be a therapeutic option for this condition.


Assuntos
Glomerulosclerose Segmentar e Focal/terapia , Transplante de Rim/efeitos adversos , Plasmaferese/métodos , Adulto , Feminino , Humanos , Transplante de Rim/métodos , Masculino , Pessoa de Meia-Idade , Recidiva , Resultado do Tratamento
5.
Nefrología (Madrid) ; 40(3): 272-278, mayo-jun. 2020. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-187525

RESUMO

La reciente aparición de la pandemia por el coronavirus SARS-CoV-2 ha impactado de forma muy importante en la población general. Los pacientes en tratamiento renal sustitutivo (TRS) no han sido ajenos a esta situación y por sus características resultan especialmente vulnerables. Presentamos los resultados del análisis del Registro COVID-19 de la S.E.N. MATERIAL Y MÉTODOS: EL Registro comenzó a funcionar el 18 de marzo de 2020. Recoge variables epidemiológicas, datos del contagio y diagnóstico, clínica acompañante, tratamientos y desenlace. Se trata de un registro "on line". Los pacientes fueron diagnosticados de infección por SARS-Cov-2 en base a los resultados de la PCR del virus, realizada tanto en pacientes que habían manifestado clínica compatible o tenían signos sospechosos como en aquellos a los que se había hecho como cribado tras algún contacto conocido con otro enfermo. RESULTADOS: A fecha 11 de abril el Registro disponía de datos de 868 pacientes, procedentes de todas las Comunidades Autónomas. La modalidad de TRS más representada es la hemodiálisis en centro (HDC) seguida de los pacientes trasplantados. La clínica de presentación es similar a la población general. Un porcentaje muy elevado (85%) requirió ingreso hospitalario, un 8% en unidades de cuidados intensivos. Los tratamientos más utilizados fueron hidroxicloroquina, lopinavirritonavir y esteroides. La mortalidad es elevada y alcanza el 23%: los pacientes fallecidos estaban con más frecuencia en HDC, desarrollaban más frecuentemente neumonía y recibían en menos ocasiones lopinavir-ritonavir y esteroides. La edad y la neumonía se asociaban de forma independiente al riesgo de fallecer. CONCLUSIONES: La infección por SARS-CoV-2 afecta ya a un número importante de pacientes españoles en TRS, fundamentalmente aquellos que están en HDC, las tasas de hospitalización son muy elevadas y la mortalidad es elevada; la edad y el desarrollo de neumonía son factores asociados a mortalidad


The recent appearance of the SARS-CoV-2 coronavirus pandemic has had a significant impact on the general population. Patients on renal replacement therapy (RRT) have not been unaware of this situation and due to their characteristics they are especially vulnerable. We present the results of the analysis of the COVID-19 Registry of the Spanish Society of Nephrology. MATERIAL AND METHODS: The Registry began operating on March 18th, 2020. It collects epidemiological variables, contagion and diagnosis data, signs and symptoms, treatments and outcomes. It is an "online" registry. Patients were diagnosed with SARS-Cov-2 infection based on the results of the PCR of the virus, carried out both in patients who had manifested compatible symptoms or had suspicious signs, as well as in those who had undergone screening after some contac, acquainted with another patient. RESULTS: As of April 11, the Registry had data on 868 patients, from all the Autonomous Communities. The most represented form of TRS is in-center hemodialysis (ICH) followed by transplant patients. Symptoms are similar to the general population. A very high percentage (85%) required hospital admission, 8% in intensive care units. The most used treatments were hydroxychloroquine, lopinavir-ritonavir, and steroids. Mortality is high and reaches 23%; deceased patients were more frequently on ICH, developed pneumonia more frequently, and received less frequently lopinavir-ritonavir and steroids. Age and pneumonia were independently associated with the risk of death. CONCLUSIONS: SARS-CoV-2 infection already affects a significant number of Spanish patients on RRT, mainly those on ICH, hospitalization rates are very high and mortality is high; age and the development of pneumonia are factors associated with mortality


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Infecções por Coronavirus/mortalidade , Pneumonia Viral/mortalidade , Betacoronavirus , Pandemias , Diálise Renal/mortalidade , Insuficiência Renal Crônica/terapia , Insuficiência Renal Crônica/virologia , Transplante de Rim/efeitos adversos , Unidades Hospitalares de Hemodiálise/estatística & dados numéricos , Infecções por Coronavirus/tratamento farmacológico , Pneumonia Viral/tratamento farmacológico , Espanha/epidemiologia , Fatores de Risco
6.
Nefrologia (Engl Ed) ; 40(3): 272-278, 2020.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-32389518

RESUMO

INTRODUCTION: The recent appearance of the SARS-CoV-2 coronavirus pandemic has had a significant impact on the general population. Patients on renal replacement therapy (RRT) have not been unaware of this situation and due to their characteristics they are especially vulnerable. We present the results of the analysis of the COVID-19 Registry of the Spanish Society of Nephrology. MATERIAL AND METHODS: The Registry began operating on March 18th, 2020. It collects epidemiological variables, contagion and diagnosis data, signs and symptoms, treatments and outcomes. It is an online registry. Patients were diagnosed with SARS-CoV-2 infection based on the results of the PCR of the virus, carried out both in patients who had manifested compatible symptoms or had suspicious signs, as well as in those who had undergone screening after some contact acquainted with another patient. RESULTS: As of April 11, the Registry had data on 868 patients, from all the Autonomous Communities. The most represented form of RRT is in-center hemodialysis (ICH) followed by transplant patients. Symptoms are similar to the general population. A very high percentage (85%) required hospital admission, 8% in intensive care units. The most used treatments were hydroxychloroquine, lopinavir-ritonavir, and steroids. Mortality is high and reaches 23%; deceased patients were more frequently on ICH, developed pneumonia more frequently, and received less frequently lopinavir-ritonavir and steroids. Age and pneumonia were independently associated with the risk of death. CONCLUSIONS: SARS-CoV-2 infection already affects a significant number of Spanish patients on RRT, mainly those on ICH, hospitalization rates are very high and mortality is high; age and the development of pneumonia are factors associated with mortality.


Assuntos
Betacoronavirus , Infecções por Coronavirus/epidemiologia , Nefrologia/estatística & dados numéricos , Pandemias , Pneumonia Viral/epidemiologia , Sistema de Registros/estatística & dados numéricos , Terapia de Substituição Renal/estatística & dados numéricos , Fatores Etários , Idoso , COVID-19 , Distribuição de Qui-Quadrado , Infecções por Coronavirus/tratamento farmacológico , Infecções por Coronavirus/mortalidade , Feminino , Unidades Hospitalares de Hemodiálise/estatística & dados numéricos , Humanos , Unidades de Terapia Intensiva/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Pneumonia Viral/tratamento farmacológico , Pneumonia Viral/mortalidade , SARS-CoV-2 , Sociedades Médicas , Espanha/epidemiologia , Estatísticas não Paramétricas , Avaliação de Sintomas/estatística & dados numéricos , Transplantados/estatística & dados numéricos
11.
Nefrología (Madr.) ; 32(6): 824-828, nov.-dic. 2012. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-110499

RESUMO

La ateroembolia de colesterol (AEC) es una enfermedad sistémica cuya incidencia ha aumentado en las últimas décadas y que presenta una elevada morbimortalidad. En el momento actual se desconocen cuáles son las alternativas terapéuticas más efectivas en esta entidad. En este artículo presentamos el caso de una paciente diagnosticada de AEC con afectación cutánea, intestinal y renal, que presentó una buena evolución tras el inicio de terapia combinada con esteroides y análogos de las prostaglandinas. A pesar de que no existen estudios concluyentes, sugerimos esta alternativa para el manejo de AEC con afectación orgánica (AU)


Cholesterol atheroembolism (CAE) is a systemic disorder whose incidence has increased in recent decades and that presents high morbidity and mortality. Although several therapeutic alternatives have been reported, there is no consensus about the best treatment for this disease. In this paper we report the case of a patient with CAE with skin, bowel and kidney involvement who presented a good response to combined therapy with steroids and prostaglandin analogues. Although there are no conclusive studies, we recommend this therapeutic alternative in the management of CAE with organic failure (AU)


Assuntos
Humanos , Embolia de Colesterol/tratamento farmacológico , Esteroides/uso terapêutico , Iloprosta/uso terapêutico , Prostaglandinas Sintéticas/uso terapêutico , Fatores de Risco , Suscetibilidade a Doenças
12.
Nefrologia ; 32(6): 824-8, 2012.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-23169366

RESUMO

Cholesterol atheroembolism (CAE) is a systemic disorder whose incidence has increased in recent decades and that presents high morbidity and mortality. Although several therapeutic alternatives have been reported, there is no consensus about the best treatment for this disease. In this paper we report the case of a patient with CAE with skin, bowel and kidney involvement who presented a good response to combined therapy with steroids and prostaglandin analogues. Although there are no conclusive studies, we recommend this therapeutic alternative in the management of CAE with organic failure.


Assuntos
Embolia de Colesterol/tratamento farmacológico , Iloprosta/uso terapêutico , Esteroides/uso terapêutico , Idoso , Quimioterapia Combinada , Feminino , Humanos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...